Draupnir Bio

Risskov, Denmark

Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.

$13.2M raised

Jul 2024

Seed

Top Investors

HTGF (High-Tech Gruenderfonds)Novo HoldingsInkefGilde HealthcareExport and Investment Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Draupnir Bio raised?

Draupnir Bio has raised $13.2M in total funding. The most recent round was Seed. The last funding was announced in July 2024.

Who are Draupnir Bio's investors?

Draupnir Bio's investors include HTGF (High-Tech Gruenderfonds), Novo Holdings, Inkef, Gilde Healthcare, Export and Investment Fund.

Where is Draupnir Bio headquartered?

Draupnir Bio is headquartered in Risskov, Denmark.

What does Draupnir Bio do?

Draupnir Bio is developing a new type of cholesterol-lowering medicine which prevents blood clots in the heart.

What stage is Draupnir Bio at?

Draupnir Bio is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 17, 2024.

MLA

"Draupnir Bio — Funding & Investors." VCBacked, July 17, 2024, https://www.vcbacked.co/company/draupnir-bio. Accessed June 7, 2026.

APA

VCBacked. (2024). Draupnir Bio — Funding & Investors. Retrieved June 7, 2026, from https://www.vcbacked.co/company/draupnir-bio

Wikipedia (cite web)

{{cite web |title=Draupnir Bio — Funding & Investors |url=https://www.vcbacked.co/company/draupnir-bio |website=VCBacked |access-date=June 7, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 17, 2024.